Qualigen Therapeutics Inc (QLGN) News

Form 8-K - Current report

Qualigen Therapeutics, Inc. Announces management changes.

CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the...

Form 8-K - Current report

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the...

Form 8-K - Current report

Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)

New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC...

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form 8-K - Current report

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the...

Form EFFECT - Notice of Effectiveness

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 3 - Initial statement of beneficial ownership of securities